Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial

被引：0
|
作者：
George, D. J. [1 ]
Pantuck, A. J. [2 ]
Figlin, R. [3 ]
Escudier, B. [4 ]
Halabi, S. [5 ]
Casey, M. [6 ]
Lin, X. [7 ]
Serfass, L. [8 ]
Frean, M. J. Lechuga [9 ]
Ravaud, A. [10 ]
机构：
[1] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[2] Ronald Reagan UCLA Med Ctr, Dept Urol, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Med Hematol Oncol, Los Angeles, CA 90048 USA
[4] Gustave Roussy Inst Cancerol, Dept Med Oncol, Villejuif, France
[5] Duke Univ, Biostat & Bioinformat, Durham, NC USA
[6] Pfizer Inc, Dept Oncol, Collegeville, PA USA
[7] Pfizer Inc, Oncol, La Jolla, CA USA
[8] Pfizer, Med, Paris, France
[9] Pfizer, Oncol, Milan, Italy
[10] Hop St Andre, CHU Bordeaux, Dept Med Oncol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
881P
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [31] CONDITIONAL DISEASE-FREE SURVIVAL IN HIGH RISK LOCALIZED RENAL CELL CARCINOMA TREATED WITH OR WITHOUT ADJUVANT SUNITINIB
    Shao, Ning
    Qu, Yuan
    Wan, Fang
    Ye, Ding
    JOURNAL OF UROLOGY, 2019, 201 (04): : E342 - E342
  • [32] Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
    Staehler, M.
    Motzer, R. J.
    George, D. J.
    Pandha, H. S.
    Donskov, F.
    Escudier, B.
    Pantuck, A. J.
    Patel, A.
    DeAnnuntis, L.
    Bhattacharyya, H.
    Ramaswamy, K.
    Zanotti, G.
    Lin, X.
    Lechuga, M.
    Serfass, L.
    Paty, J.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2098 - 2104
  • [33] Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence
    Liao, Yadi
    Zheng, Yun
    He, Wei
    Li, Qijiong
    Shen, Jingxian
    Hong, Jian
    Zou, Ruhai
    Qiu, Jiliang
    Li, Binkui
    Yuan, Yunfei
    ONCOLOGY LETTERS, 2017, 13 (02) : 984 - 992
  • [34] Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma
    Herrem, CJ
    Tatsumi, T
    Olson, KS
    Shirai, K
    Finke, JH
    Bukowski, RM
    Zhou, M
    Richmond, AL
    Derweesh, I
    Kinch, MS
    Storkus, WJ
    CLINICAL CANCER RESEARCH, 2005, 11 (01) : 226 - 231
  • [35] Association between time to disease progression (TDP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Delea, T.
    Khuu, A.
    Kay, A.
    Zheng, J.
    Baladi, J. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 430 - 430
  • [36] The Association Between Treatment (tx) Modifications Due to Adverse Events (AEs) and Overall Survival (OS) in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) Treated With Sunitinib and Sorafenib: Results From a Multi-country Study in Europe
    Oudard, S.
    Porta, C.
    Castellano, D.
    McDermott, R.
    Nathan, P.
    McCaffrey, J.
    Neary, M. P.
    Korves, C.
    Suthoff, E. Dial
    Duh, M. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S515 - S516
  • [37] Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Choueiri, T. K.
    Hessel, C.
    Halabi, S.
    Sanford, B.
    Hahn, O.
    Michaelson, M. D.
    Walsh, M.
    Olencki, T.
    Picus, J.
    Small, E. J.
    Dakhil, S.
    Scheffold, C.
    George, D. J.
    Morris, M. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] Prior therapy with rituximab (R) in patients (pts) with diffuse large B-Cell lymphoma (DLBCL) does not affect disease-free (DFS) or overall survival (OS) following high dose therapy (HDT) and autologous stem cell transplantation (ASCT).
    Thakkar, Snehal G.
    Sweetenham, John William
    Rybicki, Lisa
    Sobecks, Ronald
    Andresen, Steven
    Dean, Robert M.
    Pohlman, Brad
    Kang, Tyler Y.
    Kalaycio, Matt
    Brown, Stacey
    Bolwell, Brian J.
    BLOOD, 2006, 108 (11) : 869A - 870A
  • [39] Correlation between changes in 2-or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966-2006
    Ng, R. C.
    Pond, G. R.
    Tang, P. A.
    MacIntosh, P. W.
    Siu, L. L.
    Chen, E. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data
    Haas, Naomi B.
    Song, Yan
    Rogerio, Jaqueline Willemann
    Zhang, Su
    Carley, Christopher
    Zhu, JingJing
    Bhattacharya, Rituparna
    Signorovitch, James
    Sundaram, Murali
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (03) : 272 - 279
12345